Medical News

RSS

Ascepion, Debiopharm partner to develop and commercialize ASP-08126 for solid tumors

Debiopharm Group, a global biopharmaceutical development specialist that focuses on serious medical conditions and particularly oncology, and Ascepion Pharmaceuticals, Inc., a privately-held, biopharmaceutical company dedicated to the discovery and development of breakthrough small molecule drugs for the treatment of oncology and related diseases, have entered into an exclusive worldwide license agreement concerning the development and commercialization of ASP-08126 (called Debio 1144 by Debiopharm) a multikinase inhibitor currently in pre-clinical development.

18 Jun 2012

Updated data from ARIAD’s ponatinib pivotal trial on CML or Ph+ ALL

ARIAD Pharmaceuticals, Inc. today announced updated clinical data from the pivotal PACE trial of its investigational pan-BCR-ABL inhibitor, ponatinib, in patients with chronic myeloid leukaemia (CML) or Philadelphia-positive acute lymphoblastic leukaemia (Ph+ ALL), who are resistant or intolerant to dasatinib or nilotinib or who have the T315I mutation.

18 Jun 2012

First study to look at hotel room cleanliness

An experiment of surfaces in hotel rooms finds television remotes to be among the most heavily contaminated with bacteria and items on housekeeping carts carry the potential to cross-contaminate rooms. Researchers from the University of Houston report the findings today at the 2012 General Meeting of the American Society for Microbiology.

18 Jun 2012

NHS Supply Chain signs deal to purchase 10 Elekta Synergy radiation therapy treatment systems

NHS Supply Chain will bring state-of-the-art cancer treatment to the United Kingdom by signing a deal to purchase ten Elekta Synergy radiation therapy treatment systems.

From Elekta 18 Jun 2012

Quintiles announces agreements to expand lab testing capabilities in China

In a ceremony underscoring the growing importance of China to the global biopharmaceutical industry, Quintiles executives and local dignitaries today announced agreements to establish a Quintiles regional headquarters for China in Shanghai and to significantly expand lab testing capabilities in China.

18 Jun 2012

DBV Technologies’ Viaskin safe and effective in treating children with peanut allergy

DBV Technologies, creator of Viaskin, a new standard in the treatment of allergy, announced today that AP-HP (Assistance Public - Hôpitaux de Paris) sponsor of the ARACHILD study presented at the EAACI Congress a late breaking oral presentation on safety and efficacy data after six months of epicutaneous immunotherapy in peanut allergy using Viaskin Peanut.

18 Jun 2012

FDA completes review of compounded hydroxyprogesterone caproate products and APIs

FDA (or the Agency) approved Makena (hydroxyprogesterone caproate) in February 2011 for the reduction of the risk of certain preterm births in women who have had at least one prior preterm birth. Beginning many years before Makena was approved, a version of the active ingredient of Makena has been available to patients whose physicians requested the drug from a pharmacist who compounded the drug.

18 Jun 2012

WHO launches new tool to improve quality and human rights in mental health and social care

WHO urges countries to protect the rights and dignity of people with mental health conditions as it launches a new tool for countries to assess and eventually stop, these violations. The WHO QualityRights Tool Kit aims to ensure that quality of care and human rights standards are put in place in mental health and social care facilities around the world.

18 Jun 2012

New resource captures health insurance programs for low-income populations in developing countries

A new resource captures more than 100 health insurance programs designed for low-income populations in developing countries —an important milestone in developing a comprehensive database of this emerging industry.

18 Jun 2012

Greater Than AIDS, Walgreens partner to mark National HIV Testing Day

Walgreens, the nation's largest pharmacy chain, and Greater Than AIDS, a coalition of public and private sector partners united in response to the domestic epidemic, are teaming with health departments and local AIDS organizations to provide FREE HIV testing at 47 Walgreens stores in 20 cities across the nation in June in support of National HIV Testing Day.

18 Jun 2012

ASH, EHA and ECPC issue common call to action to mitigate hematologic drug shortages

The American Society of Hematology (ASH) joined the European Hematology Association (EHA) and the European Cancer Patient Coalition (ECPC) today in issuing a common call to action in an effort to mitigate shortages of hematologic drugs in the United States and around the world.

18 Jun 2012

High court ruling's possible effect on state Medicaid programs

The expansion of Medicaid - if it is upheld by the Supreme Court - is among the most significant parts of the law, as it will provide coverage to people with the greatest financial needs. Many health care advocates support the expansion, saying it will allow poor people to receive needed care, while many state officials, especially Republicans, worry that it will bring budget-breaking new costs.

18 Jun 2012

UW initiates enrollment in tosedostat phase II combination study for AML, MDS

Cell Therapeutics, Inc. today announced that the University of Washington has begun enrolling patients in a randomized phase II study testing the combination of tosedostat with either cytarabine or decitabine for elderly patients with newly-diagnosed acute myeloid leukemia ("AML") or high-risk myelodysplastic syndrome.

18 Jun 2012

Researchers identify commensal bacteria in the human intestine

Researchers at Baylor College of Medicine and Texas Children's Hospital have identified commensal bacteria in the human intestine that produce a neurotransmitter that may play a role in preventing or treating inflammatory bowel diseases such as Crohn's disease.

18 Jun 2012

Researchers develop double viral vector transfection technique

The collaborative research team led by Professor Tadashi ISA, Project Assistant Professor Masaharu KINOSHITA from The National Institute for Physiological Sciences, The National Institutes of Natural Sciences and Fukushima Medical University and Kyoto University, developed "the double viral vector transfection technique" which can deliver genes to a specific neural circuit by combining two new kinds of gene transfer vectors.

18 Jun 2012

100BMOA releases official statement on prostate cancer

100 Black Men of America, Inc., Chairman Albert E. Dotson, Jr., the Board of Directors and the Executive Committee of 100 Black Men of America, Inc. release an official statement on prostate cancer, in an effort to save lives of countless men who are at the highest risk of developing prostate cancer.

18 Jun 2012

In reversal, Catholic hospitals reject support for contraception compromise

In an unexpected blow to the Obama administration and a major boon for America's Catholic bishops, the influential Catholic Health Association on Friday rejected White House proposals aimed at easing faith-based objections to the contraception mandate. ... The mandate requires that all employee health insurance plans must provide no-cost birth control coverage to employees, and it grants what many consider an unacceptably narrow exemption for religious groups.

18 Jun 2012

Positive results from ERYTECH Pharma asparaginase Phase II trials on ALL

The oral presentation will be held on June 17th 2012 by Prof. Dr. Hervé Dombret, Hospital Saint Louis, Paris (France) at the 17th Annual Meeting of European Hematology Association (EHA) in Amsterdam.

18 Jun 2012

Link between unconscious conflicts and conscious anxiety disorder symptoms

An experiment that Sigmund Freud could never have imagined 100 years ago may help lend scientific support for one of his key theories, and help connect it with current neuroscience.

18 Jun 2012

Updated results from two clinical trials of Bruton's ibrutinib for CLL/SLL

Pharmacyclics, Inc announced today at the 17th Congress of European Hematology Association updated results from two clinical trials of Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765), for the treatment of patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).

18 Jun 2012